Coverage: The Meridian legal market record (editorial).
The licensed market is Egypt, so the transaction is African on the face of the primary source: an Egyptian manufacturer-distributor obtains commercial rights to a Chinese-origin oncology portfolio for the Egyptian market.
| Record ID | TX-AFR-2025-0010 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Trade mark licence, In-licensing |
| IP rights | trade mark, regulatory data |
| Status | Announced |
| Qualifying date | 2025-03-26 |
| Sector | Life sciences · Pharmaceuticals – oncology |
| African markets | Egypt |
| Licensed territory | Egypt. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- EVA Pharma (Egypt): licensee
- BeiGene: licensor
Key terms
- Interest: licence (commercialisation); Exclusivity: not stated by source; Territorial scope: Egypt; Field of use: Oncology
Sources
- EVA Pharma and BeiGene Announce a Strategic Partnership to Bring Innovative Oncology Therapies to Patients in Egypt, EVA Pharma, 2025-03-26
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


